Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 69-74 , January 2009

Baroreflex stimulation: A novel treatment option for resistant hypertension

  • Sankar D. Navaneethan, MD, MPH

      Affiliations

    • Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    • ,
  • Thomas E. Lohmeier, PhD

      Affiliations

    • Department of Physiology, University of Mississippi Medical Center, Jackson, Mississippi, USA
    • ,
  • John D. Bisognano, MD, PhD

      Affiliations

    • Department of Internal Medicine, Cardiology Division, University of Rochester Medical Center, Rochester, New York, USA
    • Corresponding Author InformationCorresponding author: John D. Bisognano, MD, PhD, Director of Outpatient Cardiology, University of Rochester, Cardiology Division, 601 Elmwood Avenue, Box 679, Rochester, New York 14642. Tel: 585-275-6168; fax: 585-276-0073

Received 18 July 2008 ,Accepted 24 September 2008.

References 

  1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton P, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223
  2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC-7 report. JAMA. 2003;289:2560–2572
  3. American Heart Association. Hypertension statistics. http://www.americanheart.org/presenter.jhtml?identifier=4621Accessed: August 18, 2008
  4. Messreli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370:591–603
  5. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–2398
  6. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–1315
  7. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a quantitative overview updated until March 1, 2003. J Hypertens. 2003;21:1055–1076
  8. Moser M, Setaro JF. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355:385–392
  9. Alderman MH, Budner N, Cohen H, Lamport B, Ooi WL. Prevalence of drug resistant hypertension. Hypertension. 1988;11:S71–S75
  10. Chapleau M. Arterial baroreflexes (Hypertension primer: the essentials of high blood pressure). In: 2nd ed.. London, England: Lippincott Williams & Wilkins; 1999;p. 83
  11. Neistadt A, Schwartz S. Effects of electrical stimulation of the carotid sinus nerve in reversal of experimentally induced hypertension. Surgery. 1967;61:923–931
  12. Andresen MC, Doyle MW, Jin YH, Bailey TW. Cellular mechanisms of baroreceptor integration at the nucleus tractus solitarius. Ann N Y Acad Sci. 2001;940:132–141
  13. Chapleau MW, Li Z, Meyrelles SS, Ma X, Abboud FM. Mechanisms determining sensitivity of baroreceptor afferents in health and disease. Ann NY Acad Sci. 2001;940:1–19
  14. Snitsarev V, Whiteis CA, Chapleau MW, Abboud FM. Neuronal prostacyclin is an autocrine regulator of arterial baroreceptor activity. Hypertension. 2005;46:540–546
  15. Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13:S99–S105
  16. Lohmeier TE, Hildebrandt DA, Warren S, May PJ, Cunningham JT. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol. 2005;288:R828–R836
  17. Filippone JD, Bisognano JD. Baroreflex stimulation in the treatment of hypertension. Curr Opin Nephrol Hypertens. 2007;16:403–408
  18. Lohmeier TE. The sympathetic nervous system and long-term blood pressure regulation. Am J Hypertens. 2001;14:S147–S154
  19. Bristow JD, Honour AJ, Pickering GW, Sleight P, Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation. 1969;39:48–54
  20. Maton G. Carotid sinus and neurogenic and renal hypertension. J Physiol. 1954;126:13–14
  21. McCubbin JW, Green JH, Page IH. Baroreceptor function in chronic renal hypertension. Circ Res. 1956;4:205–210
  22. Lohmeier TE, Lohmeier JR, Reckelhoff JF, Hildebrandt DA. Sustained influence of the renal nerves to attenuate sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol. 2001;281:R434–R443
  23. Lohmeier TE, Loheimer JR, Warren S, May PJ, Cunningham JT. Sustained activation of the central baroreceptor pathway in angiotensin hypertension. Hypertension. 2002;39:550–556
  24. Lohmeier TE, Irwin E, Rossing M, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43:306–311
  25. Lohmeier TE, Dwyer TM, Hildebrandt DA, Irwin ED, Rossing MA, Serdar DJ, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotenisn hypertension. Hypertension. 2005;46:1194–1200
  26. Lohmeier TE, Lohmeier JR, Haque A, Hildebrandt DA. Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1437–R1448
  27. Lohmeier TE, Warren S, Cunningham JT. Sustained activation of the central baroreceptor pathway in obesity hypertension. Hypertension. 2003;42:96–102
  28. Lohmeier TE, Dwyer TM, Irwin ED, Rossing MA, Kieval RS. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007;49:1307–1314
  29. Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, et al. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension. 2007;49:373–379
  30. Thrasher TN. Unloading arterial baroreceptors causes neurogenic hypertension. Am J Physiol Regul Integr Comp Physiol. 2002;282:R1044–R1053
  31. Thrasher TN. Effects of chronic baroreceptor unloading on blood pressure in the dog. Am J Physiol Regul Integr Comp Physiol. 2005;288:R863–R871
  32. Carlsten A, Folkow B, Grimby G, Hamberger CA, Thulesius O. Cardiovascular effects of direct simulation of the carotid sinus nerve in man. Acta Physiol Scanda. 1958;44:138–145
  33. Bilgutay A, Lillehei W. Treatment of hypertension with an implantable electronic device. JAMA. 1965;191:113–117
  34. Schwartz S, Griffith L, Neistadt A, Hagfors N. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg. 1967;114:5–15
  35. Braunwald E, Zipes D, Lippy P. Heart Disease: A Textbook of Cardiovascular Medicine. In: Philadelphia, Pennsylvania: W.B. Saunders Company; 2001;p. 2173
  36. Tuckman J, Reich T, Lyon A, Goodman B, Mendlowitz M, Jacobson J. Electrical stimulation of the sinus nerves in hypertensive patients: clinical evaluation and physiological studies. Hypertension. 1967;194:S23–S38
  37. Peters T, Koralewski H, Zerbst E. The principle of electrical carotid sinus nerve stimulation: a nerve pacemaker system for angina pectoris and hypertension therapy. Ann Biomed Eng. 1980;8:445–458
  38. Peters TK, Koralewski HE, Zerbst E. Search for optimal frequencies and amplitudes of therapeutic electrical carotid sinus nerve stimulation by application of the evolution strategy. Artif Organs. 1989;3:133–143
  39. Bisognano J, Sloand J, Papademetriou V, Rothstein M, Sica D, Flack J, et al. An implantable carotid sinus baroreflex activating system for drug-resistant hypertension: interim chronic efficacy results from the multicenter Rheos feasibility trial. Circulation. 2006;S114:II575
  40. Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, et al. An implantable carotid sinus stimulator for drug resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44:1213–1218
  41. Tordoir JHM, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B, et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multicenter feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg. 2007;33:414–421
  42. Rheos pivotal trial. Available online at: http://www.clinicaltrials.gov/ct2/show/NCT00442286?term=Rheos&;rank=1. Accessed: August 18, 2008.

 Dr. Bisognano has received research support and consulting fees from the manufacturer of the Device, CVRx. Dr. Lohmeier has received consulting fees from CVRx.

PII: S1933-1711(08)00182-4

doi: 10.1016/j.jash.2008.09.001

Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 69-74 , January 2009

Article Tools